Physicians' Academy for Cardiovascular Education

Atrial fibrillation, stroke & anticoagulation

News - Dec. 27, 2012

 

Atrial fibrillation and stroke: Disease awareness

Slide lecture program (20 slides): View & Download

  1. AF is a cardiac arrhythmia associated with rapid and irregular atrial impulses
  2. AF can be symptomatic and asymptomatic
  3. Classification of AF is determined according to presentation and duration
  4. Risk factors for AF: overview
  5. The number of patients with AF is anticipated to increase
  6. Stroke: a major healthcare burden
  7. Stroke is a major consequence of AF
  8. AF is a significant risk factor for ischaemic stroke
  9. Proportion of strokes attributable to AF increases with age
  10. AF-related strokes are more severe than non-AF-related strokes
  11. Outcomes in stroke patients with AF are more severe than in patients without AF
  12. Strokes in patients with AF are more severe than in patients without AF
  13. The increased disability that results from AF-related stroke persists over time
  14. AF increases annual mortality rates following first-ever ischaemic stroke
  15. Among stroke survivors, AF increases the likelihood of recurrent stroke
  16. Why are AF-related strokes more severe?
  17. AF-related stroke: a major economic burden
  18. AF-related stroke: impact on individuals and society
 

Screening and diagnosis of AF and stratifying stroke risk

Slide lecture program (8 slides): View & Download

  1. AF can be symptomatic and asymptomatic
  2. The time course of AF
  3. Guideline recommendations for the detection and diagnosis of AF
  4. Characteristics of an ECG recording for a patient with AF
  5. Systematic versus opportunistic screening: the SAFE study
  6. How can we achieve earlier diagnosis of AF?
 

Stratifying stroke risk to guide antithrombotic therapy in patients with AF

Slide lecture program (12 slides): View & Download

  1. No evidence that AF type significantly impacts stroke risk
  2. Stroke Risk in AF Working Group: factors influencing stroke risk in patients with AF
  3. Different schemes designed to stratify stroke risk in patients with AF
  4. Differences in risk stratification schemes yield varying degrees of stroke risk
  5. CHADS2 is the most recognized risk stratification scheme
  6. ACCF/AHA/HRS 2011 and ACCP 2008 guidelines: based on CHADS2
  7. CHA2DS2-VASc: a further refinement of CHADS2
  8. ESC 2010 guidelines: based on CHADS2 and CHA2DS2-VASc
  9. Many stroke risk factors are also risk factors for bleeding
  10. 1-year risk of major bleeding increases with HAS-BLED score
  11. ATRIA: a risk scheme to predict warfarin-associated haemorrhage
 

Management of AF­related stroke

Slide lecture program (23 slides): View & Download

  1. Strategies for prevention of stroke in AF
  2. Key studies of VKA and antiplatelet therapy for stroke prevention in AF
  3. ACCF/AHA/HRS 2011 and ACCP 2008 guidelines: based on CHADS2
  4. ESC 2010 guidelines: based on CHADS2 and CHA2DS2-VASc
  5. VKA limitations
  6. VKAs have a narrow therapeutic window
  7. Non-adherence to guidelines is associated with poorer outcomes: Euro Heart Survey
  8. Rationale for novel oral anticoagulants
  9. Newer oral anticoagulants for stroke prevention in AF: clinical trial overview
  10. Phase III trials: study design and baseline data
  11. RE-LY: dabigatran vs warfarin
  12. RE-LY: primary efficacy endpoints
  13. RE-LY: bleeding outcomes
  14. RE-LY: other outcomes
  15. ROCKET AF: rivaroxaban vs warfarin
  16. ROCKET AF: primary efficacy endpoint
  17. ROCKET AF: bleeding outcomes
  18. ROCKET AF: other outcomes
  19. ARISTOTLE: apixaban vs warfarin
  20. ARISTOTLE: primary efficacy endpoint
  21. ARISTOTLE: bleeding outcomes
  22. ARISTOTLE: other outcomes

Share this page with your colleagues and friends: